University of Wisconsin–Madison

Emily R. Winslow, MD, FACS

Associate Professor

  • Division of Surgical Oncology
  • Divisions of General Surgery
(608) 262-2025

600 Highland Avenue
Box 7375, Clinical Science Center
Madison, WI 53792-7375


  • MD, Harvard Medical School, Boston, MA, 1999
  • Residency in Internal Medicine, Boston University School of Medicine, Boston, MA, 2000
  • Residency in General Surgery, Washington University School of Medicine, St. Louis, MO, 2000-2006
  • Fellowship in Hepatopancreaticobiliary Surgery, Washington University School of Medicine, St. Louis, MO, 2007
  • Fellowship in Transplant Surgery, Northwestern Memorial Hospital, Chicago, IL, 2009

Clinical Specialties

Dr. Winslow specializes in benign and malignant disease in the liver, bile duct, and pancreas. She performs both laparoscopic and open liver and pancreas surgery. She has specific clinical interest in patients with pancreatic cancer, cholangiocarcinoma, metatstatic colorectal cancer, and bile duct injuries. She is certified by the American Board of Surgery.

Research Interests

Dr. Winslow conducts clinical research in patients with pancreatic cancer and neuroendocrine tumors. She is also interested in outcomes studies in patients with hepatobiliary malignancies. She is currently pursuing a master’s degree in Clinical Investigation at the Institute for Clinical and Translational Research, with the goal of developing a research program focused on patient-centered outcomes in surgical oncology.

Dr. Winslow presents on effective patient communication as part of a UW Health panel (2018)

Recent Publications

    • Adaptation and Implementation of a Transitional Care Protocol for Patients Undergoing Complex Abdominal Surgery.
    • Fisher AV, Campbell-Flohr SA, Sell L, Osterhaus E, Acher AW, Leahy-Gross K, Brenny-Fitzpatrick M, Kind AJH, Carayon P, Abbott DE, Winslow ER, Greenberg CC, Fernandes-Taylor S, Weber SM
    • Jt Comm J Qual Patient Saf 2018 Aug 07;
    • [PubMed ID: 30097384]
    • Analysis of 90-day cost for open versus minimally invasive distal pancreatectomy.
    • Fisher AV, Fernandes-Taylor S, Schumacher JR, Havlena JA, Wang X, Lawson EH, Ronnekleiv-Kelly SM, Winslow ER, Weber SM, Abbott DE
    • HPB (Oxford) 2018 Jul 31;
    • [PubMed ID: 30076011]
    • The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer.
    • Fisher AV, Abbott DE, Venkatesh M, Leverson GE, Campbell-Flohr SA, Ronnekleiv-Kelly SM, Greenberg CC, Winslow ER, Weber SM
    • Ann. Surg. Oncol. 2018 Jul 12;
    • [PubMed ID: 30003452]
    • A Prospective, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Fibrin Sealant Grifols as an Adjunct to Hemostasis as Compared to Cellulose Sheets in Hepatic Surgery Resections.
    • Bjelović M, Ayguasanosa J, Kim RD, Stojanović M, Vereczkei A, Nikolić S, Winslow E, Emre S, Xiao G, Navarro-Puerto J, Courtney K, Barrera G, investigators of the Fibrin Sealant Grifols in Hepatic Resection Clinical Investigation Study Group
    • J. Gastrointest. Surg. 2018 Jul 02;
    • [PubMed ID: 29967969]
    • Grading Using Ki-67 Index and Mitotic Rate Increases the Prognostic Accuracy of Pancreatic Neuroendocrine Tumors.
    • Philips P, Kooby DA, Maithel S, Merchant NB, Weber SM, Winslow ER, Ahmad S, Kim HJ, Scoggins CR, McMasters KM, Martin RCG
    • Pancreas 2018 03; 47(3): 326-331
    • [PubMed ID: 29351120]

All Publications on PubMed